• Explore /
  • Poster
  • / Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly <i>RAS</i> and <i>BRAF</i> wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.

Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.

Abstract Poster

Authors

null

Roberto Moretto

Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy

Roberto Moretto , Francesca Battaglin , Carlotta Antoniotti , Federica Buggin , Laura Delliponti , Francesca Bergamo , Chiara Cremolini , Antonella Brunello , Marta Schirripa , Alice Menichetti , Lisa Salvatore , Valentina Angela Marsico , Daniele Rossini , Laura Rumano' , Federica Marmorino , Alfredo Falcone , Vittorina Zagonel , Fotios Loupakis , Sara Lonardi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

2015-003888-10

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS3627)

DOI

10.1200/JCO.2016.34.15_suppl.TPS3627

Abstract #

TPS3627

Poster Bd #

322b

Abstract Disclosures

Similar Posters

First Author: Takanori Watanabe

First Author: Evaristo Maiello

First Author: Carlos Alberto Mayo

First Author: Hirokazu Shoji